Monitor the July 30 webinar for any disclosed private placement terms (price, dilution, use of proceeds) and clinical trial updates on the Phase 2b osteoarthritis study—the filing itself contains no tradable numbers.
Price Chart
Executive Summary
Enlivex filed a 6-K announcing a management webinar on July 30, 2026, to discuss its recently completed private placement, the status of its RAIN treasury strategy, and clinical progress for Allocetra (including a new FDA RMAT designation). The filing provides no new financial data, deal terms, or clinical results—only an invitation and agenda.
Key Facts
- Webinar scheduled for July 30, 2026 at 10:00 AM ET to discuss private placement, RAIN treasury strategy, and clinical progress.
- Allocetra (cell therapy for osteoarthritis) was recently granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation.
- No financial figures, private placement size/pricing, or revenue data included in the filing.
- Company market cap ~$38M with 86% analyst bullish consensus per provided snapshot.
Financial Impact
Not specified
Risk Factors
- No concrete financial data or deal terms disclosed in this filing.
- The RAIN token treasury strategy introduces significant volatility and correlation risk between ENLV shares and crypto markets.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-082559 |
| Document: ea029961701ex99-1.htm | 0001213900-26-082559 |
| Document: 0001213900-26-082559-index-headers.html | 0001213900-26-082559 |
| Document: 0001213900-26-082559-index.html | 0001213900-26-082559 |
| Document: 0001213900-26-082559.txt | 0001213900-26-082559 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.1734 | awaiting T+5 | — | $2.56 (−1379.12%) |
Oct 22, 2026 5d ago | 6-K | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 22, 2026 5d ago | Press Release | $0.1734 | awaiting T+5 | — | $2.56 (+1379.12%) |
Oct 19, 2026 8d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Oct 19, 2026 8d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.56 (−1139.03%) |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | $2.56 (+398.99%) |
Sep 22, 2026 5w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | $2.56 (+296.78%) |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | $2.56 (+62.33%) |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | $2.56 (+31.53%) |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | $2.56 (+13.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers